UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest
event reported): June 16, 2008
_________________________
Auriga
Laboratories, Inc.
(Exact
name of registrant as specified in its charter)
_________________________
|
Delaware
|
000-26013
|
84-1334687
|
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
5284
Adolfo Road, Camarillo, California 93012
(Address
of principal executive office) (zip code)
Registrant's
telephone number, including area code: (805) 437-7200
N/A
(Former
name or former address, if changed since last report)
_________________________
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction
A.2. below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Section
5 – Corporate Governance and Management
Item 5.02 Departure of Directors or Certain
officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
On
January 24, 2008, the Company issued a press release announcing the appointment
of Frank Greico to the position of Chief Executive Officer and election as a
Director of The Board of Directors of the Company (hereinafter, the
“Board”). Mr. Greico assumed the position of Chief Executive Officer
in addition to his role as Chief Financial Officer. Also, at that time, the
Board elected Elliot Maza, JD, CPA, to the office of Chairman of the
Board.
The Board
has determined that it is in the best interests of the Company’s employees,
creditors and shareholders to separate the roles of Chief Executive Officer and
Chief Financial Officer. Therefore, effective June 16, 2008, Mr. Greico is
reverting to his role of Chief Financial Officer, at the compensation level
specified in his contract for such role, and the Board is considering candidates
to fill the position of Chief Executive Officer. In the interim, Mr. Maza will
increase his participation in the management of the Company and will
resign from the Audit Committee of the Board.
Mr. Maza
became a director in May 2007, and Chairman of the Board on January 23,
2008. He also serves as Chairman of the Board’s Audit Committee and a
member of the Compensation Committee. Mr. Maza is a licensed C.P.A.
and attorney and has extensive experience in the pharmaceutical and drug
development industries. Mr. Maza is currently President and Chief Financial
Officer and a member of the Board of Directors of Intellect Neurosciences, Inc.
(OTC: ILNS), a New York-based biotechnology company. Prior to joining
Intellect, from December 2003 to May 2006, Mr. Maza was Chief
Financial Officer of Emisphere Technologies (NASDAQ: EMIS), a biopharmaceutical
company specializing in oral drug delivery. Previously, he was a
partner at Ernst and Young LLP and a Vice President at Goldman Sachs, Inc., and
JP Morgan Securities, Inc. Mr. Maza also practiced law at Sullivan
and Cromwell. Mr. Maza received his J.D. degree from the University of
Pennsylvania Law School and his Bachelor of Arts from Touro College
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, Auriga Laboratories,
Inc. has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Dated:
June 17, 2008
|
AURIGA
LABORATORIES, INC.
|
|
|
|
|
|
|
|
|
By:
/s/ Elliot M. Maza
|
|
|
Elliot
M. Maza
|
|
|
Chairman
of the Board
|